Literature DB >> 2299203

Effect of rimantadine on cytotoxic T lymphocyte responses and immunity to reinfection in mice infected with influenza A virus.

J E Herrmann1, K West, M Bruns, F A Ennis.   

Abstract

Administration of rimantadine to mice via drinking water, following a prophylactic dose, reduced lung virus titers by greater than 3 log10 plague-forming units (pfu)/ml but caused only marginal reductions in lung virus titers when therapy was started 8 h after exposure to virus. Mice given rimantadine prophylactically plus therapeutically were resistant to rechallenge with virus at a dose equivalent to that used for the primary infection (50 pfu/mouse) but not to a high dose (1 x 10(5) pfu/mouse). Virus-neutralizing-antibody titers were reduced only by rimantadine treatment, which included prophylaxis, whereas the cytotoxic T lymphocyte (CTL) response was depressed by treatment given with or without prophylaxis. Mice infected with rimantadine-resistant virus had no decrease in CTL or antibody responses when treated with rimantadine. Therefore, the depression in CTL and antibody responses associated with rimantadine treatment appears to be due to a decrease in the amount of viral antigen available or interference with viral antigen processing and not to nonspecific immunosuppressive effects.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2299203     DOI: 10.1093/infdis/161.2.180

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  2 in total

1.  Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations.

Authors:  Yacine Abed; Nathalie Goyette; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

2.  Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine.

Authors:  F G Hayden; S J Sperber; R B Belshe; R D Clover; A J Hay; S Pyke
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.